|
1
|
Boehm T, Folkman J, Browder T and O’Reilly
MS: Antiangiogenic therapy of experimental cancer does not induce
acquired drug resistance. Nature. 390:404–407. 1997. View Article : Google Scholar
|
|
2
|
Li J, Dong X, Xu Z, Jiang X, Jiang H,
Krissansen GW and Sun X: Endostatin gene therapy enhances the
efficacy of paclitaxel to suppress breast cancers and metastases in
mice. J Biomed Sci. 15:99–109. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Herbst RS, Hess KR, Tran HT, Tseng JE,
Mullani NA, Charnsangavej C, Madden T, Davis DW, McConkey DJ,
O’Reilly MS, Ellis LM, Pluda J, Hong WK and Abbruzzese JL: Phase I
study of recombinant human endostatin in patients with advanced
solid tumors. J Clin Oncol. 20:3792–3803. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Felbor U, Dreier L, Bryant RA, Ploegh HL,
Olsen BR and Mothes W: Secreted cathepsin L generates endostatin
from collagen XVIII. EMBO J. 19:1187–1194. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lin HC, Chang JH, Jain S, Gabison EE, Kure
T, Kato T, Fukai N and Azar DT: Matrilysin cleavage of corneal
collagen type XVIII NC1 domain and generation of a 28-kDa fragment.
Invest Ophthalmol Vis Sci. 42:2517–2524. 2001.PubMed/NCBI
|
|
6
|
Wen W, Moses MA, Wiederschain D, Arbiser
JL and Folkman J: The generation of endostatin is mediated by
elastase. Cancer Res. 59:6052–6056. 1999.PubMed/NCBI
|
|
7
|
Ferreras M, Felbor U, Lenhard T, Olsen BR
and Delaisse J: Generation and degradation of human endostatin
proteins by various proteinases. FEBS Lett. 486:247–251. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sudhakar A, Sugimoto H, Yang C, Lively J,
Zeisberg M and Kalluri R: Human tumstatin and human endostatin
exhibit distinct antiangiogenic activities mediated by αvβ3 and
α5β1 integrins. Proc Natl Acad Sci USA. 100:4766–4771.
2003.PubMed/NCBI
|
|
9
|
Karumanchi SA, Jha V, Ramchandran R,
Karihaloo A, Tsiokas L, Chan B, Dhanabal M, Hanai JI, Venkataraman
G, Shriver Z, Keiser N, Kalluri R, Zeng H, Mukhopadhyay D, Chen RL,
Lander AD, Hagihara K, Yamaguchi Y, Sasisekharan R, Cantley L and
Sukhatme VP: Cell surface glypicans are low-affinity endostatin
receptors. Mol Cell. 7:811–822. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ling Y, Yang Y, Lu N, You QD, Wang S, Gao
Y, Chen Y and Guo QL: Endostar, a novel recombinant human
endostatin, exerts antiangiogenic effect via blocking VEGF-induced
tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem
Biophys Res Commun. 361:79–84. 2007. View Article : Google Scholar
|
|
11
|
Kim YM, Hwang S, Kim YM, Pyun BJ, Kim TY,
Lee ST, Gho YS and Kwon YG: Endostatin blocks vascular endothelial
growth factor-mediated signaling via direct interaction with
KDR/Flk-1. J Biol Chem. 277:27872–27879. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim YM, Jang JW, Lee OH, Yeon J, Choi EY,
Kim KW, Lee ST and Kwon YG: Endostatin inhibits endothelial and
tumor cellular invasion by blocking the activation and catalytic
activity of matrix metalloproteinase. Cancer Res. 60:5410–5413.
2000.PubMed/NCBI
|
|
13
|
Hanai J, Dhanabal M, Karumanchi SA,
Albanese C, Waterman M, Chan B, Ramchandran R, Pestell R and
Sukhatme VP: Endostatin causes G1 arrest of endothelial cells
through inhibition of cyclin D1. J Biol Chem. 277:16464–16469.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shichiri M and Hirata Y: Antiangiogenesis
signals by endostatin. FASEB J. 15:1044–1053. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hebbar M, Peyrat JP, Hornez L, Hatron PY,
Hachulla E and Devulder B: Increased concentrations of the
circulating angiogenesis inhibitor endostatin in patients with
systemic sclerosis. Arthritis Rheum. 43:889–893. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Funatsu H, Yamashita H, Noma H, Shimizu E,
Yamashita T and Hori S: Stimulation and inhibition of angiogenesis
in diabetic retinopathy. Jpn J Ophthalmol. 45:577–584. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ma L, del Soldato P and Wallace JL:
Divergent effects of new cyclooxygenase inhibitors on gastric ulcer
healing: Shifting the angiogenic balance. Proc Natl Acad Sci USA.
99:13243–13247. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hajitou A, Grignet C, Devy L, Berndt S,
Blacher S, Deroanne CF, Bajou K, Fong T, Chiang Y, Foidart JM and
Noël A: The antitumoral effect of endostatin and angiostatin is
associated with a down-regulation of vascular endothelial growth
factor expression in tumor cells. FASEB J. 16:1802–1804.
2002.PubMed/NCBI
|
|
19
|
Maione TE, Gray GS, Petro J, Hunt AJ,
Donner AL, Bauer SI, Carson HF and Sharpe RJ: Inhibition of
angiogenesis by recombinant human platelet factor-4 and related
peptides. Science. 247:77–79. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vogel T, Guo N, Krutzsch HC, Blake DA,
Hartmann J, Mendelovitz S, Panet A and Roberts DD: Modulation of
endothelial cell proliferation, adhesion and motility by
recombinant heparin-binding domain and synthetic peptides from the
type I repeats of thrombospondin. J Cell Biochem. 53:74–84. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
O’Reilly MS, Holmgren L, Shing Y, Chen C,
Rosenthal RA, Moses M, Lane WS, Chao Y, Sage EH and Folkman J:
Angiostatin: a novel angiogenesis inhibitor that mediates the
suppression of metastases by a Lewis lung carcinoma. Cell.
79:315–328. 1994.PubMed/NCBI
|
|
22
|
O’Reilly MS, Boehm T, Shing Y, Fukai N,
Vasois G, Lane WS, Flynn E, Birkhead JR, Olsen BR and Folkman J:
Endostatin: an endogenous inhibitor of angiogenesis and tumor
growth. Cell. 88:277–285. 1997.
|
|
23
|
Good DJ, Polverini PJ, Rastinejad F, Le
Beau MM, Lemons RS, Frazier WA and Bouck NP: A tumor
suppressor-dependent inhibitor of angiogenesis is immunologically
and functionally indistinguishable from a fragment of
thrombospondin. Proc Natl Acad Sci USA. 87:6624–6628. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tolsma SS, Volpert OV, Good DJ, Frazier
WA, Polverini PJ and Bouck N: Peptides derived from two separate
domains of the matrix protein thrombospondin-1 have anti-angiogenic
activity. J Cell Biol. 122:497–511. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dawson DW, Pearce SF, Zhong R, Silverstein
RL, Frazier WA and Bouck NP: CD36 mediates the in vitro inhibitory
effects of thrombospondin-1 on endothelial cells. J Cell Biol.
138:707–717. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cao Y, Ji RW, Davidson D, Schaller J,
Marti D, Söhndel S, McCance SG, O’ Reilly M, Llinás M and Folkman
J: Kringle domains of human angiostatin. Characterization of the
anti-proliferative activity on endothelial cells. J Biol Chem.
271:29461–29467. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dhanabal M, Ramchandran R, Volk R, et al:
Endostatin: yeast production, mutants, and antitumor effect in
renal cell carcinoma. Cancer Res. 59:189–197. 1999.PubMed/NCBI
|
|
28
|
Peroulis I, Jonas N and Saleh M:
Antiangiogenic activity of endostatin inhibits C6 glioma growth.
Int J Cancer. 97:839–845. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yokoyama Y, Sedgewich G and Ramakrishnan
S: Endostatin binding to ovarian cancer cells inhibits peritoneal
attachment and dissemination. Cancer Res. 67:10813–10822. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu F, Tan G, Li J, et al: Gene transfer
of endostatin enhances the efficacy of doxorubicin to suppress
human hepatocellular carcinomas in mice. Cancer Sci. 98:1381–1387.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hoffmann S, Wunderlich A, Celik I, et al:
Paneling human thyroid cancer cell lines for candidate proteins for
targeted antiangiogenic therapy. J Cell Biochem. 98:954–965. 2006.
View Article : Google Scholar : PubMed/NCBI
|
